Minocin, Emrosi (minocycline) dosing, indications, interactions, adverse effects, and more (2025)

Acne Vulgaris

Immediate-release: 50-100 mg PO BID

Extended-release tablets: 1 mg/kg PO daily

Administer therapy for 12 weeks

Rosacea

Emrosi

• Indicated to treat inflammatory lesions of rosacea in adults
• 40 mg PO daily

Purulent Cellulitis (Off-label)

Community acquired MRSA: 200 mg PO initially

Maintenance: 100 mg PO twice daily for 5-10 days

Chlamydial or Ureaplasma Urealyticum

Uncomplicated infection: 100 mg PO q12hr for at least 7 days

Gonococcal Infection

Uncomplicated infection in males (no anorectal infections or presence of urethritis: 200 mg PO initially)

Maintenance: 100 mg PO twice daily for at least 4 days

Uncomplicated gonococcal urethritis in men: 100 mg PO q12hr for 5 days

Meningococcal Carrier State

100 mg PO q12hr for 5 days

Urethral, Endocervical, or Rectal Infections

Caused by C. trachomatis or U. urealyticum (uncomplicated infection): 100 mg PO q12hr for 7 days

Mycobacterium marinum

100 mg PO q12hr for 6-8 weeks

Syphilis

200 mg PO initially, followed by 100 mg q12hr for 10-15 days

Rheumatoid Arthritis (Off-label)

100 mg PO twice daily

Infective Endocarditis

100 mg IV twice daily for at least 5 weeks

Infections, General Dosing

200 mg PO/IV initially, THEN 100 mg PO/IV q12hr; not to exceed 400 mg/day, OR

Alternatively, 200 mg PO initially, THEN 100 mg PO q12hr; OR 100-200 mg initially; THEN 50 mg PO q6hr

Dosage Modifications

Renal impairment: Reduce dose and/or frequency

Dosing Considerations

Limitations of use

• Emrosi

  • Has not been evaluated for treatment or prevention of infections
  • To reduce development of drug-resistant bacteria as well as maintaining effectiveness of other antibacterial drugs, use only as indicated

Susceptible organisms

• Acinetobacter baumannii, Actinomyces spp, Afipia felis, Bacteroides spp, Bartonella bacilliformis, Borrelia recurrentis, Brucella spp, Burkholderia cepacia, Klebsiella granulomatis, Campylobacter jejuni, Chlamydia spp, Clostridium spp, Coxiella burnetii, Eikenella corrodens, Escherichia coli, Entamoeba spp, Francisella tularensis, Haemophilus ducreyi, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, Mycoplasma hominis, Mycoplasma pneumoniae, Neisseria meningitidis, Neisseria gonorrhoeae, Nocardia asteroides, Prevotella melaninogenica, Propionibacterium acnes, Rickettsiae, Shigella spp, MRSA, Streptococcus pneumoniae, Streptococcus pyogenes, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholerae, Yersinia pestis, Yersinia enterocolitica, Yersinia pseudotuberculosis, mycobacteria other than tuberculosis

Sarcoidosis (Orphan)

Orphan indication sponsor

• Autoimmunity Research Foundation; Autoimmunity Research, Inc; Thousand Oaks, CA 91360

Acne Vulgaris

<12 years: Safety and efficacy not established

Immediate-release products: 4 mg/kg PO initially (not to exceed 200 mg), THEN 2 mg/kg/day PO divided q12hr; not to exceed 200 mg BID

Extended-release tablets: 1 mg/kg PO daily

Administer therapy for 12 weeks

C trachomatis or U urealyticum

100 mg PO q12hr for 7 days

Infections, General Dosing

≤8 years: Not recommended, unless unable to take other, alternate antibiotics

>8 years: 4 mg/kg PO/IV initially; not to exceed 200 mg; THEN 2 mg/kg PO/IV q12hr; not to exceed adult dose; not to exceed 100 mg PO/IV q12hr for 5-10 days

Dosing Considerations

Susceptible organisms

• Acinetobacter baumannii, Actinomyces spp, Afipia felis, Bacteroides spp, Bartonella bacilliformis, Borrelia recurrentis, Brucella spp, Burkholderia cepacia, Klebsiella granulomatis, Campylobacter jejuni, Chlamydia spp, Clostridium spp, Coxiella burnetii, Eikenella corrodens, Escherichia coli, Entamoeba spp, Francisella tularensis, Haemophilus ducreyi, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, Mycoplasma hominis, Mycoplasma pneumoniae, Neisseria meningitidis, Neisseria gonorrhoeae, Nocardia asteroides, Prevotella melaninogenica, Propionibacterium acnes, Rickettsiae, Shigella spp, MRSA, Streptococcus pneumoniae, Streptococcus pyogenes, Treponema pallidum, Ureaplasma urealyticum, Vibrio cholerae, Yersinia pestis, Yersinia enterocolitica, Yersinia pseudotuberculosis, mycobacteria other than tuberculosis

Enter a drug name to check for any interactions. + minocycline

Contraindicated (2)

• acitretin

  minocycline, acitretin. Other (see comment). Contraindicated. Comment: Both acitretin and tetracyclines can cause increased intracranial pressure.

• tretinoin

  minocycline, tretinoin.Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Both tretinoin and tetracyclines can cause increased intracranial pressure.

Serious (56)

• aluminum hydroxide

  aluminum hydroxide decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

• aminolevulinic acid oral

  aminolevulinic acid oral, minocycline.Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period.

• aminolevulinic acid topical

  minocycline increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.

• amoxicillin

  minocycline decreases effects of amoxicillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Tetracyclines may interfere with the bactericidal action of penicillins. Monitor for decreased therapeutic effects of penicillins if concomitantly used with a tetracycline.

• ampicillin

  minocycline decreases effects of ampicillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Tetracyclines may interfere with the bactericidal action of penicillins. Monitor for decreased therapeutic effects of penicillins if concomitantly used with a tetracycline.

• atracurium

  minocycline increases effects of atracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.

• BCG vaccine live

  minocycline decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.

• bismuth subsalicylate

  bismuth subsalicylate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• calcium acetate

  calcium acetate, minocycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

• calcium carbonate

  calcium carbonate, minocycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

• calcium chloride

  calcium chloride, minocycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

• calcium citrate

  calcium citrate, minocycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

• calcium gluconate

  calcium gluconate, minocycline.Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

• carbonyl iron

  carbonyl iron decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• cholera vaccine

  minocycline, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.

• cisatracurium

  minocycline increases effects of cisatracurium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.

• dicloxacillin

  minocycline decreases effects of dicloxacillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug.

• ferric maltol

  ferric maltol decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• ferrous fumarate

  ferrous fumarate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• ferrous gluconate

  ferrous gluconate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• ferrous sulfate

  ferrous sulfate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• iron dextran complex

  iron dextran complex decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• iron sucrose

  iron sucrose decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• isotretinoin

  isotretinoin, minocycline. Mechanism: unknown. Contraindicated. Risk of pseudotumor cerebri.

• magnesium chloride

  magnesium chloride decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• magnesium citrate

  magnesium citrate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• magnesium hydroxide

  magnesium hydroxide decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• magnesium oxide

  magnesium oxide decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• magnesium sulfate

  magnesium sulfate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• methoxyflurane

  minocycline, methoxyflurane. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of nephrotoxicity.

• methyl aminolevulinate

  minocycline, methyl aminolevulinate.Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.

• microbiota oral

  minocycline decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. .

• nafcillin

  minocycline decreases effects of nafcillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. bacteriostatic antibiotics may interfere with the bactericidal actions of penicillins.

• oxacillin

  minocycline decreases effects of oxacillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. bacteriostatic agents may inhibit the effects of bactericidal agents.

• palovarotene

  minocycline, palovarotene. Other (see comment). Avoid or Use Alternate Drug. Comment: Systemic retinoid use has been associated with cases of benign intracranial hypertension (pseudotumor cerebri), some of which involved concomitant use of tetracyclines.

• pancuronium

  minocycline increases effects of pancuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.

• penicillin G aqueous

  minocycline decreases effects of penicillin G aqueous by pharmacodynamic antagonism. Avoid or Use Alternate Drug.

• penicillin VK

  minocycline decreases effects of penicillin VK by pharmacodynamic antagonism. Avoid or Use Alternate Drug.

• pexidartinib

  minocycline and pexidartinib both increase Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity.

• polysaccharide iron

  polysaccharide iron decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• pretomanid

  minocycline, pretomanid.Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid.

• rapacuronium

  minocycline increases effects of rapacuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.

• rocuronium

  minocycline increases effects of rocuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.

• rose hips

  rose hips decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• sodium bicarbonate

  sodium bicarbonate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

• sodium citrate/citric acid

  sodium citrate/citric acid decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

• sodium sulfate/?magnesium sulfate/potassium chloride

  sodium sulfate/?magnesium sulfate/potassium chloride decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Administer tetracyclines at least 2 hr before and no less than 6 hr after each dose to avoid chelation with magnesium. .

• sodium sulfate/potassium sulfate/magnesium sulfate

  sodium sulfate/potassium sulfate/magnesium sulfate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Administer tetracyclines at least 2 hr before and no less than 6 hr after each dose to avoid chelation with magnesium. .

• strontium ranelate

  strontium ranelate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Suspend strontium ranelate during antibiotic therapy.

• succinylcholine

  minocycline increases effects of succinylcholine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.

• temocillin

  minocycline decreases effects of temocillin by pharmacodynamic antagonism. Avoid or Use Alternate Drug.

• tretinoin

  minocycline, tretinoin.Either increases levels of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.

• tretinoin topical

  minocycline, tretinoin topical. Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. Increased phototoxicity.

• tripotassium dicitratobismuthate

  tripotassium dicitratobismuthate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug.

• typhoid vaccine live

  minocycline decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.

• vecuronium

  minocycline increases effects of vecuronium by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of respiratory depression.

Monitor Closely (36)

• bazedoxifene/conjugated estrogens

  minocycline will decrease the level or effect of bazedoxifene/conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

• cefdinir

  minocycline decreases effects of cefdinir by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.

• cefditoren

  minocycline decreases effects of cefditoren by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.

• cefoxitin

  minocycline decreases effects of cefoxitin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.

• cefpodoxime

  minocycline decreases effects of cefpodoxime by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.

• ceftriaxone

  minocycline decreases effects of ceftriaxone by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.

• cefuroxime

  minocycline decreases effects of cefuroxime by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.

• cholestyramine

  cholestyramine decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

• conjugated estrogens

  minocycline will decrease the level or effect of conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

• dichlorphenamide

  dichlorphenamide, minocycline.Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

• didanosine

  didanosine will decrease the level or effect of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Applies to didanosine chewable tablets and powder for oral solution; administer 2 hr before or several hours after didanosine oral solution or chewable tablet administration

• digoxin

  minocycline will increase the level or effect of digoxin by altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.

• dihydroergotamine

  minocycline, dihydroergotamine.Either increases toxicity of the other by Mechanism: unknown. Use Caution/Monitor. coadministration of ergot alkaloids and tetracyclines increases risk of ergotism.

• ergoloid mesylates

  minocycline, ergoloid mesylates.Either increases toxicity of the other by Mechanism: unknown. Use Caution/Monitor. coadministration of ergot alkaloids and tetracyclines increases risk of ergotism.

• ergotamine

  minocycline, ergotamine.Either increases toxicity of the other by Mechanism: unknown. Use Caution/Monitor. coadministration of ergot alkaloids and tetracyclines increases risk of ergotism.

• estradiol

  minocycline will decrease the level or effect of estradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

• estrogens conjugated synthetic

  minocycline will decrease the level or effect of estrogens conjugated synthetic by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

• estropipate

  minocycline will decrease the level or effect of estropipate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

• ethinylestradiol

  minocycline will decrease the level or effect of ethinylestradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

• lanthanum carbonate

  lanthanum carbonate decreases levels of minocycline by cation binding in GI tract. Use Caution/Monitor. Administer oral tetracycline antibiotics at least 2 hr before or after lanthanum. Interaction applies only to oral tetracyclines.

• levonorgestrel oral/ethinylestradiol/ferrous bisglycinate

  minocycline will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy.

• magnesium supplement

  magnesium supplement will decrease the level or effect of minocycline by Other (see comment). Modify Therapy/Monitor Closely. Formation of an insoluble complex reduces absorption of the drug through intestinal tract; administer magnesium 2hr before the tetracycline or 4hr after the tetracycline.

• mestranol

  minocycline will decrease the level or effect of mestranol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.

• methotrexate

  minocycline increases levels of methotrexate by decreasing elimination. Use Caution/Monitor. If tetracyclines cannot be avoided in patients receiving high-dose methotrexate, closely monitor methotrexate plasma concentrations and patients for signs and symptoms of toxicity.

• methoxsalen

  methoxsalen, minocycline.Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects.

• methylergonovine

  minocycline, methylergonovine.Either increases toxicity of the other by Mechanism: unknown. Use Caution/Monitor. coadministration of ergot alkaloids and tetracyclines increases risk of ergotism.

• mipomersen

  mipomersen, minocycline.Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.

• piperacillin

  minocycline decreases effects of piperacillin by pharmacodynamic antagonism. Use Caution/Monitor. bacteriostatic agents may inhibit the effects of bactericidal agents.

• polycarbophil

  polycarbophil decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

• porfimer

  minocycline, porfimer. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Enhanced photosensitivity.

• sodium picosulfate/magnesium oxide/anhydrous citric acid

  minocycline decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.sodium picosulfate/magnesium oxide/anhydrous citric acid decreases levels of minocycline by cation binding in GI tract. Use Caution/Monitor. Take at least 2 hours before and not less than 6 hours after administration of sodium picosulfate, magnesium oxide and anhydrous citric acid to avoid magnesium chelation.

• tobramycin inhaled

  tobramycin inhaled and minocycline both increase nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity

• trimagnesium citrate anhydrous

  trimagnesium citrate anhydrous decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of tetracyclines; administer tetracycline at least 2 hr before or 6 hr after magnesium; use alternatives if available.

• valoctocogene roxaparvovec

  minocycline and valoctocogene roxaparvovec both increase Other (see comment). Use Caution/Monitor. Medications that may cause hepatotoxicity when combined with valoctogene roxaparvovec may potentiate the risk of elevated liver enzymes. Closely monitor these medications and consider alternative medications in case of potential drug interactions.

• warfarin

  minocycline increases effects of warfarin by unspecified interaction mechanism. Use Caution/Monitor.

• zinc

  zinc will decrease the level or effect of minocycline by cation binding in GI tract. Modify Therapy/Monitor Closely. Separate administration of oral tetracycline derivatives and oral zinc salts by at least 2 hr.

Minor (23)

• antithrombin alfa

  minocycline increases effects of antithrombin alfa by pharmacodynamic synergism. Minor/Significance Unknown.

• antithrombin III

  minocycline increases effects of antithrombin III by pharmacodynamic synergism. Minor/Significance Unknown.

• argatroban

  minocycline increases effects of argatroban by pharmacodynamic synergism. Minor/Significance Unknown.

• balsalazide

  minocycline will decrease the level or effect of balsalazide by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

• bemiparin

  minocycline increases effects of bemiparin by pharmacodynamic synergism. Minor/Significance Unknown.

• biotin

  minocycline will decrease the level or effect of biotin by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

• bivalirudin

  minocycline increases effects of bivalirudin by pharmacodynamic synergism. Minor/Significance Unknown.

• colestipol

  colestipol decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

• dalteparin

  minocycline increases effects of dalteparin by pharmacodynamic synergism. Minor/Significance Unknown.

• enoxaparin

  minocycline increases effects of enoxaparin by pharmacodynamic synergism. Minor/Significance Unknown.

• fondaparinux

  minocycline increases effects of fondaparinux by pharmacodynamic synergism. Minor/Significance Unknown.

• heparin

  minocycline increases effects of heparin by pharmacodynamic synergism. Minor/Significance Unknown.

• niacin

  minocycline will decrease the level or effect of niacin by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

• pantothenic acid

  minocycline will decrease the level or effect of pantothenic acid by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

• phenindione

  minocycline increases effects of phenindione by pharmacodynamic synergism. Minor/Significance Unknown.

• protamine

  minocycline increases effects of protamine by pharmacodynamic synergism. Minor/Significance Unknown.

• pyridoxine

  minocycline will decrease the level or effect of pyridoxine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

• pyridoxine (Antidote)

  minocycline will decrease the level or effect of pyridoxine (Antidote) by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

• rose hips

  minocycline decreases levels of rose hips by increasing elimination. Minor/Significance Unknown.

• sucralfate

  sucralfate decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

• thiamine

  minocycline will decrease the level or effect of thiamine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.

• verteporfin

  minocycline, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity.

• vitamin A

  minocycline, vitamin A. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of benign intracranial hypertension.

Print

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

• View the formulary and any restrictions for each plan.
• Manage and view all your plans together – even plans in different states.
• Compare formulary status to other drugs in the same class.
• Access your plan list on any device – mobile or desktop.